The cheapest legitimate way to get tirzepatide in 2026 is either commercial insurance plus the Lilly Savings Card (copays as low as $25 per month for Mounjaro; $25 to $550 per 3-month supply for Zepbound) or the Lilly Direct Zepbound vial self-pay program ($349 for 2.5 mg starter, $499 for 5 mg and higher). Compounded tirzepatide is largely gone after the FDA declared the shortage resolved in October 2024 with enforcement deadlines in early 2025. Avoid overseas or “research use only” sellers — these are illegal and often dangerous.
All Legitimate Paths Compared
| Path | Monthly Cost | Requires | Who Qualifies |
|---|---|---|---|
| Commercial insurance + Mounjaro Savings Card | $25 | T2D diagnosis, PA approval | Most commercially insured T2D patients |
| Commercial insurance + Zepbound Savings Card | $25–$550 (3-mo supply) | Weight-loss eligibility, PA approval | Commercially insured patients meeting BMI criteria |
| Lilly Direct Zepbound vial (2.5 mg) | $349 | Prescription | Self-pay users at starter dose |
| Lilly Direct Zepbound vial (5 mg+) | $499 | Prescription | Self-pay users at maintenance dose |
| Medicare Part D (Mounjaro) | Standard Part D copay ($10-$100) | T2D diagnosis | Medicare enrollees with T2D |
| Medicare for OSA (select plans, Zepbound) | Varies by plan | OSA diagnosis + BMI ≥ 30 | Some Medicare enrollees with OSA |
| Lilly Cares patient assistance | Free or low cost | Low income, uninsured | US residents meeting income criteria |
| GoodRx retail discount | $900–$1,000 | Nothing | Anyone with prescription |
| Retail cash (no program) | $1,100–$1,400 | Prescription | Anyone |
| Clinical-need compounding exception | Varies | Documented clinical need not met by branded | Rare; requires specific clinical justification |
Option 1: Lilly Direct Zepbound Vials
- $349 per month for 2.5 mg starter dose
- $499 per month for 5, 7.5, 10, 12.5, and 15 mg maintenance doses
- Requires a prescription from a licensed US clinician
- Requires a Lilly Direct account
- Ships as single-dose vials with separate syringes
- Self-injection required — learn the technique from your clinician or instructional video
- No insurance involvement
- No prior authorization
- Available only for Zepbound (not Mounjaro)
- Telehealth platforms can prescribe for Lilly Direct fulfillment
Option 2: Commercial Insurance + Savings Cards
Mounjaro Savings Card (Type 2 Diabetes)
- Commercial insurance copay can be reduced to $25 per month
- Annual savings cap applies (typically up to $1,950 per year for most plans)
- Not valid for Medicare, Medicaid, or other government-funded prescription plans
- Register at the Mounjaro savings card website or through your provider
Zepbound Savings Card (Weight Loss)
- Commercial insurance copay can be reduced — typical floors are $25 per month or $550 per 3-month supply
- Annual savings cap typically up to $1,950 per year
- Not valid for Medicare, Medicaid, VA, or other government plans
- Register at the Zepbound savings card website
- Plans vary widely — some cover Zepbound generously, others do not cover for weight loss at all
Prior Authorization Tips
- Document BMI, weight-related comorbidities, and prior weight-loss attempts
- For diabetes, document A1C, medication history (metformin trialed), and current regimen
- Appeal first-pass denials in writing — many succeed on appeal
- Your clinician’s office can usually help submit the PA
Option 3: Medicare
Mounjaro for Type 2 Diabetes
- Covered under Part D for most Medicare beneficiaries with T2D
- Standard Part D cost-sharing applies (initial, initial coverage, coverage gap, catastrophic phases)
- 2025 Part D out-of-pocket cap is $2,000 per year; check 2026 updates
- Typical copay ranges from $10 to $100 per month depending on plan tier
Zepbound for Weight Loss
- Not covered by Medicare for weight-loss-only indication
- Some Part D plans cover Zepbound for moderate-to-severe obstructive sleep apnea (FDA-approved indication as of 2024) if BMI ≥ 30
- Check your specific Part D plan’s formulary
- Medicare Advantage (Part C) plans may cover weight-loss drugs more broadly in some cases — check plan details
Option 4: Lilly Cares Patient Assistance
- Free or low-cost medication for eligible US residents
- Income eligibility: typically up to 300 to 400 percent of federal poverty level
- Requires application and documentation
- Available for both Mounjaro and Zepbound
- Apply at lillycares.com or through your clinician
Why Compounded Tirzepatide Is No Longer Cheap
Compounded tirzepatide was widely available through telehealth at $200 to $400 per month during the 2022–2024 FDA shortage period. Status now:
- October 2, 2024: FDA declared tirzepatide shortage resolved
- February 18, 2025: 503A compounding pharmacies required to stop
- March 19, 2025: 503B outsourcing facilities required to stop
- Narrow clinical-need exceptions remain but are not a general path
- Telehealth platforms that still advertise “compounded tirzepatide” are either operating under narrow exceptions, selling a different product, or operating outside US law
If your telehealth platform still offers compounded tirzepatide in 2026, ask exactly what regulatory basis they use. Reputable providers will answer transparently.
Red Flags on “Cheap” Tirzepatide
- Price under $200 per month without a clear pharmacy or program
- Ships from India, China, or Mexico
- Labeled “research use only”
- Advertised as “tirzepatide sodium” or “tirzepatide acetate” — FDA has stated salt forms are not the same drug
- No prescription or clinician consultation required
- Crypto-only or wire-transfer payment
- Social-media-only sales (Instagram, Facebook DM)
- No named pharmacy, pharmacist, or US state license
- No physical US address
Step-By-Step Decision Tree
- Do you have commercial insurance? → Call insurance + use Lilly Savings Card → often $25/mo for Mounjaro or low-cost Zepbound
- Do you have Medicare and T2D? → Part D covers Mounjaro at standard copays
- Do you have Medicare, no T2D, and BMI ≥ 30 with OSA? → Check if plan covers Zepbound for OSA
- Are you uninsured or under-insured with low income? → Apply to Lilly Cares
- Are you self-pay, primarily want weight loss? → Lilly Direct Zepbound vials ($349 or $499)
- Are you self-pay, Mounjaro needed, and no insurance? → GoodRx discount ($900–$1,000), then explore Lilly Cares
Related Reading
See our guides on treatment options and reversibility strategies.
The Bottom Line
In 2026, the cheapest legitimate way to get tirzepatide is commercial insurance plus the Lilly Savings Card (often $25 per month for Mounjaro, $25 to $550 per 3-month supply for Zepbound) or the Lilly Direct Zepbound vial self-pay program ($349 or $499 per month). Medicare covers Mounjaro for diabetes; Zepbound for weight loss is generally not covered except for OSA on some plans. Compounded tirzepatide is no longer broadly available after the FDA shortage resolution. Avoid overseas or “research use only” sellers — these are illegal and risky. Work through the decision tree with your clinician to find the cheapest path for your specific situation.
